<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597906</url>
  </required_header>
  <id_info>
    <org_study_id>N-18-2018</org_study_id>
    <nct_id>NCT03597906</nct_id>
  </id_info>
  <brief_title>Topography Guided LASIK by Different Protocols for Treatment of Astigmatism</brief_title>
  <official_title>Comparison of the Outcome of Topography Modified Refraction Correction to Standard Clinical Refraction Correction in Myopic Astigmatic Topography-guided LASIK</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and Rationale:&#xD;
&#xD;
      LASIK has been among the highest satisfaction rates of surgical procedures, ranging from&#xD;
      82%-98%. Different ablation profiles have been developed over the years. The purpose of this&#xD;
      study is to validate this novel measurement by comparing the visual outcomes when the TMR is&#xD;
      used in myopic astigmatic LASIK to using the standard manifest refraction or the Topolyzer&#xD;
      measurements alone.&#xD;
&#xD;
      Objectives :&#xD;
&#xD;
      To evaluate the safety, efficacy and predictability of topography-guided myopic LASIK with&#xD;
      three different refraction treatment strategies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Candidates for refractive surgery above 18 years with myopic astigmatism and no previous&#xD;
      ocular surgery.&#xD;
&#xD;
      Sample size 60 eyes. surgery:&#xD;
&#xD;
        -  60 eyes of myopic topography-guided LASIK procedures with the same refractive platform&#xD;
           (FS200 femtosecond to create a flap between90: 110 μm with diameter 8:9 mm and EX500&#xD;
           excimer lasers) will be randomized for treatment as follows:&#xD;
&#xD;
        -  Group A: 20 eyes will be treated using Contoura vision with the standard manifest&#xD;
           refraction.&#xD;
&#xD;
        -  Group B: 20 eyes will be treated with Contoura vision using the topographic astigmatic&#xD;
           power and axis and without change in the spherical power (using the same spherical power&#xD;
           as the manifest refraction).&#xD;
&#xD;
        -  Group C [TMR]: 20 eyes will be treated with Contoura vision using the topographic&#xD;
           astigmatic power and axis and modifying the spherical power to obtain the same spherical&#xD;
           equivalent as the manifest refraction. This is done by subtracting half of the&#xD;
           difference between topographic astigmatic power and the manifest astigmatic power from&#xD;
           the spherical power (topography-modified treatment refraction).&#xD;
&#xD;
        -  The standard postoperative treatment is combined steroids and antibiotics eye drops 5&#xD;
           times daily for one week ,then three times daily for three days and lubricant eye drops&#xD;
           5 times daily for six months.&#xD;
&#xD;
      Postoperatively, the patients will be examined at 1 week, 1 month and 3 months. All&#xD;
      postoperative follow-up visits included measurement of UDVA, CDVA (if indicated) and&#xD;
      refraction, besides full ophthalmological examination and performing pentacam and topolyzer&#xD;
      after 3 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Actual">January 20, 2020</completion_date>
  <primary_completion_date type="Actual">November 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective, randomized and comparative interventional study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>post operative residual astigmatism</measure>
    <time_frame>3 months</time_frame>
    <description>measuring the post operative residual astigmatism and comparison between the 3 group to reach to the most accurate protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measurement of the postoperative unaided visual acuity</measure>
    <time_frame>3 months</time_frame>
    <description>measurement of the postoperative unaided visual acuity and comparison between the 3 group to reach to the most accurate protocol.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Refractive Surgery</condition>
  <arm_group>
    <arm_group_label>Group A: Manifest</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 eyes will be treated using Contoura, topography guided ablation vision with the standard manifest refraction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: partial TMR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and without change in the spherical power (using the same spherical power as the manifest refraction).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: Full TMR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and modifying the spherical power to obtain the same spherical equivalent as the manifest refraction. This is done by subtracting half of the difference between topographic astigmatic power and the manifest astigmatic power from the spherical power (topography-modified treatment refraction).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>topography guided ablation</intervention_name>
    <description>using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols</description>
    <arm_group_label>Group A: Manifest</arm_group_label>
    <arm_group_label>Group B: partial TMR</arm_group_label>
    <arm_group_label>Group C: Full TMR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>manifest refraction</intervention_name>
    <description>using for ablation the exact manifest refraction</description>
    <arm_group_label>Group A: Manifest</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>full topography modified refraction</intervention_name>
    <description>full topography modified refraction means changing both sphere and cylinder power in the ablation profile</description>
    <arm_group_label>Group C: Full TMR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>partial topography modified refraction</intervention_name>
    <description>partial topography modified refraction means changing only cylinder power and axis in the ablation profile</description>
    <arm_group_label>Group B: partial TMR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stable refractive error: Myopic astigmatism ≥ -1.5 D&#xD;
&#xD;
          -  Valid Topolyzer maps (at least four out of eight right maps with green analyzed area&#xD;
             and the registration box is green).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Estimated postoperative residual stromal bed thickness of less than 300µm.&#xD;
&#xD;
          2. Glaucomatous patients.&#xD;
&#xD;
          3. Patients with keratoconus.&#xD;
&#xD;
          4. Patients with pervious refractive surgery.&#xD;
&#xD;
          5. History of previous ocular trauma or surgery.&#xD;
&#xD;
          6. History of recent herpetic ulcer or viral keratitis.&#xD;
&#xD;
          7. Basement membrane disease, history of recurrent corneal erosions.&#xD;
&#xD;
          8. Sicca syndrome, dry eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohmed Hosny, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kasr Alainy</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 21, 2018</study_first_submitted>
  <study_first_submitted_qc>July 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>January 26, 2020</last_update_submitted>
  <last_update_submitted_qc>January 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Fayrouz Aboalazayem</investigator_full_name>
    <investigator_title>the principal investigator</investigator_title>
  </responsible_party>
  <keyword>Topography guided ablation</keyword>
  <keyword>Astigmatism</keyword>
  <keyword>LASIK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

